Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mikael Dolsten
Biotech
Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders
Former CBER chief Peter Marks leaps to Lilly. OSE swaps out CEO. Mikael Dolsten settles into board chair at cancer biotech.
Darren Incorvaia
,
Zoey Becker
Oct 10, 2025 8:30am
Incyte, FDA, Sun Pharma and more—Chutes & Ladders
Jun 27, 2025 8:30am
Sage CMO steps down amid pipeline struggles—Chutes & Ladders
Mar 7, 2025 8:30am
Pfizer taps replacement for long-time R&D leader Dolsten
Nov 20, 2024 10:25am
Mikael Dolsten to leave Pfizer, sparking search for successor
Jul 9, 2024 8:50am
Mikael Dolsten preps Pfizer's entry into obesity's 2nd wave
Feb 13, 2024 9:50am
